Skip to content

Railroad Therapeutics

Active
Private limited companyfounded 2022active for 4 yearsRue Clément Ader 10, 6041 Charleroi, Belgium36 active companies are registered at this addressKBO/BCE: BE 0792.976.285
Summary

Railroad Therapeutics has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €437,751 and a net result of -€127,809. Equity is growing by about 369% per year across the filed financial years. Its solvency ranks better than 60% of 613 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisFollow ReportCompare
Railroad TherapeuticsActiveChecked score 90/100
Risk analysis ReportCompare

Overview

Activity
Research and development on biotechnology
NACE 72101
1 site
Size
€619,622total assets 2025
Staff
1 FTE
Equity
€437,751
Loss
-€127,809
Turnover not published (micro format)
Financial health
90 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Structure
Largest shareholder
6K venture capital · 10.18%
Board
6 members
2025 accounts 3 days early4 of 5 deeds summarised
Why 90raises riskLoss of €127,809, the second in a row (financial year 2025)1 change of registered office in 24 monthslowers riskLiquidity: current ratio 18.16, cash €529,988Sector: Scientific research and development (NACE 72)Show the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 67% of its sector peers (NACE 72, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 96+96
equity 70.6% of total assets
Liquidity 100=
short-term debt 5.5% · cash 85.5%
Profitability 0-50
return on assets -20.6%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (935 companies, NACE 72, micro)
Last 24 months 11-2024: 0.8% 12-2024: 0.8%● unchanged vs 11-2024 01-2025: 0.7%▼ -0.1 percentage points vs 12-2024 02-2025: 0.7%● unchanged vs 01-2025 03-2025: 0.7%● unchanged vs 02-2025 04-2025: 0.8%▲ +0.1 percentage points vs 03-2025 05-2025: 0.8%● unchanged vs 04-2025 06-2025: 0.7%▼ -0.1 percentage points vs 05-2025 07-2025: 1.1%▲ +0.4 percentage points vs 06-2025 08-2025: 1.5%▲ +0.4 percentage points vs 07-2025highest value 09-2025: 1.5%● unchanged vs 08-2025 10-2025: 1.5%● unchanged vs 09-2025 11-2025: 1.5%● unchanged vs 10-2025 12-2025: 1.5%● unchanged vs 11-2025 01-2026: 1.5%● unchanged vs 12-2025 02-2026: 1.5%● unchanged vs 01-2026 03-2026: 1.4%▼ -0.1 percentage points vs 02-2026 04-2026: 1.4%● unchanged vs 03-2026 05-2026: 1.4%● unchanged vs 04-2026 06-2026: 1.3%▼ -0.1 percentage points vs 05-2026 07-2026: 1.2%▼ -0.1 percentage points vs 06-2026 08-2026: 0.2%▼ -1.0 percentage point vs 07-2026 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.2%● unchanged vs 09-2026lowest value
Credit of up to €35,000 on 30-day terms is acceptable
Liquidity ample (current ratio 18.16, compared with 14.71 in 2024, above the usual 1.5; short-term debt: 5.5% and cash: 85.5% of total assets), and 29.4% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 62% on solvency, 96% on liquidity, 10% on profitability and 99% on growth.

The bankruptcy probability was computed on 27-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 18.16, cash €529,988
NBB · annual accounts
raises risk · Loss of €127,809, the second in a row (financial year 2025)
NBB · annual accounts
lowers risk · Sector: Scientific research and development (NACE 72)
KBO
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-07-2026, 3 days ahead of the deadline.
NBB · 3 filings
Deviation from the deadline
2025
3 days early
2024
20 days late
2023
128 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average 48 days after the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 20 August (3 of the last 3 filed years within 109 days of that day).
Companies Code · seven months
Where today falls in the filing period
28-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2022.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · micro…
  2. Resignation: Sambrinvest SA (director)Appointment: 6K VENTURE CAPITAL SA…
  3. Weakest financial yearnet -€127,809

Key points

  • Caution: Among the weakest 5% on net resultsector median €26,700 · 613 companies -€127,809 View
  • Caution: 2 loss-making years in a rowloss financial year 2025 -€127,809 View
  • A director leftlatest change 27-02-2026 · 6 in office 1 left View

By topic

Financials

Financial year
2025
Total assets
€619,622
Loss
-€127,809
Solvency
70.6%
Total assets▲ 331%
Net result
20232025
Go to Financials

Board & ownership

Board
6 members
Largest shareholder
6K venture capital · 10.18%
  • 6K venture capitalDirector
  • SambrinvestDirector
  • SCIENSATIONDirector
  • SWIERCZ JakubDirector
  • Sofie PATTYNDirector

and 1 other director

Go to Board & ownership

Timeline

Events
10
Since
2023
Next accounts
by 31-07-2027
  1. 31-12-2025Equity above €200,000
  2. 15-09-2025Appointments: Yvan SERGEANT (director) and Sofie PATTYN…
  3. 20-08-2025Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Research and development on biotechnologyNACE 72101
Founded
27-10-2022
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
11
Who signs
Each director alone
Purpose
“La conception,la planification,la conduite,l’analyse et la publication d’études de…” (deed in French)
Go to Articles of association

Key facts about Railroad Therapeutics

What is the company number of Railroad Therapeutics?
0792.976.285. In Belgium the VAT number is the company number with BE in front: BE 0792.976.285.
Where is Railroad Therapeutics based?
The registered office is at Rue Clément Ader 10, 6041 Charleroi.Company details
What does Railroad Therapeutics do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of Railroad Therapeutics?
Private limited company (BV).
When was Railroad Therapeutics founded?
On 27-10-2022.
Is Railroad Therapeutics still active?
Yes, Railroad Therapeutics is an active enterprise in the KBO register.
How many employees does Railroad Therapeutics have?
On average 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of Railroad Therapeutics?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is Railroad Therapeutics profitable?
In financial year 2025, Railroad Therapeutics made a loss of €127,809.
Where can I find the annual accounts of Railroad Therapeutics?
Railroad Therapeutics filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Railroad Therapeutics due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to Railroad Therapeutics

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure